Douglas Lane & Associates LLC decreased its position in Haleon PLC Sponsored ADR (NYSE:HLN - Free Report) by 2.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,546,637 shares of the company's stock after selling 145,753 shares during the quarter. Douglas Lane & Associates LLC owned 0.15% of Haleon worth $58,920,000 as of its most recent SEC filing.
A number of other large investors also recently added to or reduced their stakes in HLN. Western Wealth Management LLC purchased a new position in Haleon in the 1st quarter valued at approximately $29,000. Annis Gardner Whiting Capital Advisors LLC raised its stake in shares of Haleon by 402.0% in the first quarter. Annis Gardner Whiting Capital Advisors LLC now owns 3,002 shares of the company's stock valued at $30,000 after acquiring an additional 2,404 shares in the last quarter. Parkside Financial Bank & Trust raised its stake in shares of Haleon by 20.4% in the second quarter. Parkside Financial Bank & Trust now owns 6,233 shares of the company's stock valued at $58,000 after acquiring an additional 1,055 shares in the last quarter. Gryphon Financial Partners LLC purchased a new position in Haleon in the first quarter valued at $101,000. Finally, NWF Advisory Services Inc. purchased a new position in Haleon in the first quarter valued at $102,000. 6.67% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several equities analysts have recently issued reports on the company. Weiss Ratings reiterated a "hold (c)" rating on shares of Haleon in a research note on Friday, September 25th. Deutsche Bank Aktiengesellschaft restated a "sell" rating on shares of Haleon in a research note on Wednesday, September 9th. Royal Bank Of Canada reiterated a "sector perform" rating on shares of Haleon in a research note on Tuesday, August 11th. Jefferies Financial Group reiterated a "buy" rating on shares of Haleon in a report on Wednesday, September 23rd. Finally, Rothschild & Co Redburn downgraded shares of Haleon from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, June 16th. Two equities research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy".
Read Our Latest Stock Analysis on Haleon
Haleon Stock Performance
Haleon stock traded up $0.04 during mid-day trading on Friday, reaching $9.29. 7,238,202 shares of the company were exchanged, compared to its average volume of 10,443,843. The firm's 50-day simple moving average is $9.56 and its two-hundred day simple moving average is $9.51. Haleon PLC Sponsored ADR has a twelve month low of $8.65 and a twelve month high of $11.28. The firm has a market cap of $40.88 billion, a PE ratio of 23.83, a price-to-earnings-growth ratio of 2.03 and a beta of 0.14. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.52 and a current ratio of 0.69.
Haleon Cuts Dividend
The business also recently declared a dividend, which was paid on Thursday, September 17th. Stockholders of record on Friday, August 14th were issued a $0.0642 dividend. The ex-dividend date was Friday, August 14th. This represents a dividend yield of 132.0%. This is a drop from Haleon's previous dividend of $0.1307. Haleon's payout ratio is 30.77%.
About Haleon
(
Free Report)
Haleon plc NYSE: HLN is a global consumer healthcare company headquartered in Weybridge, England. The company develops, manufactures and markets over-the-counter medicines, oral healthcare products, nutritional supplements and other consumer health products sold through pharmacies, retailers and e-commerce channels.
Its portfolio includes well-known brands such as Sensodyne, Polident and parodontax in oral healthcare; Advil, Panadol, Voltaren and Theraflu in pain relief and respiratory care; and Centrum and Emergen-C in vitamins, minerals and supplements.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Haleon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haleon wasn't on the list.
While Haleon currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
